Article
Endocrinology & Metabolism
Pepijn van Houten, Romana T. Netea-Maier, Johannes W. Smit
Summary: Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer, and the incidence of small clinically indolent tumors has been increasing. However, DTC-related mortality has remained unchanged. The management of DTC recently underwent a critical appraisal, focusing on reducing unnecessary burden for low-risk patients and identifying those who require more intensive treatment and follow-up. This review discusses recent developments in diagnosis, staging, and management of DTC, emphasizing an individualized risk assessment-based approach.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Elena Russo, Mathilda Guizzardi, Luca Canali, Francesca Gaino, Andrea Costantino, Gherardo Mazziotti, Andrea Lania, Silvia Uccella, Luca Di Tommaso, Fabio Ferreli, Luca Malvezzi, Giuseppe Spriano, Giuseppe Mercante
Summary: This meta-analysis showed no association between NLR, PLR, LMR and DFS in differentiated thyroid carcinoma (DTC). However, more prospective data are needed to better define the association between inflammatory status and prognosis of DTC.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2023)
Article
Immunology
Han Jiang, Zhaohui Li, Long Yu, Ying Zhang, Li Zhou, Jianhua Wu, Jing Yuan, Mengyao Han, Tao Xu, Junwen He, Shan Wang, Chengfeng Yu, Sha Pan, Min Wu, Hangyu Liu, Haihong Zeng, Zhu Song, Qiangqiang Wang, Shen Qu, Junwei Zhang, Yafei Huang, Junyan Han
Summary: The study revealed that VKH patients have abnormal activation and differentiation of peripheral lymphocytes, and GC therapy with methylprednisolone (MP) can suppress the pathogenic immune response by directly inhibiting T cell activation and affecting monocyte subsets.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Endocrinology & Metabolism
Wei Du, Xiangyu Shi, Qigen Fang, Xu Zhang, Shanting Liu
Summary: In the study of using apatinib to treat RAIR-DTC, patients had high objective response rate and disease control rate. The median progression-free survival and overall survival were 18 and 59 months, respectively. Adverse events were common but mostly mild to moderate.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Li Zhang, Shanshan Zheng, Yan Qin, Xuelian Chen, Shengyu Zhou
Summary: This study aimed to explore the efficacy of immune checkpoint inhibitors (ICIs) combined with kinase inhibitors (KIs) or chemotherapy (CT) for anaplastic thyroid carcinoma (ATC) or poorly differentiated thyroid carcinoma (PDTC). The results suggest that the combination therapy of ICIs with CT or KIs may achieve a better therapeutic effect and early use of ICIs could be beneficial for patients with ATC or PDTC.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Oncology
Yi Shao, Xinru Gui, Yuxin Wang, Lei Sheng, Dong Sun, Qingdong Zeng, Huayang Wang
Summary: This study analyzed the association between serum levels of soluble immune checkpoints (sICs) and cervical lymph node metastasis (CLNM) in patients with differentiated thyroid carcinoma (DTC). The results showed that higher sTIM-3 levels were associated with CLNM and postoperative sTIM-3 levels decreased. This provides evidence for predicting CLNM and surgical decision-making in DTC.
Article
Biochemistry & Molecular Biology
Hang-Seok Chang, Yonjung Kim, So Young Lee, Hyeok Jun Yun, Ho-Jin Chang, Ki Cheong Park
Summary: Thyroid cancer can be curable but may recur after treatment. In this study, a novel SERCA inhibitor was identified in sorafenib-resistant thyroid cancer cells, which showed significant tumor shrinkage in a xenograft tumor model. These findings have important clinical implications for developing new strategies to target refractory cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Antonio Mario Bulfamante, Eleonora Lori, Maria Irene Bellini, Elisa Bolis, Paolo Lozza, Luca Castellani, Alberto Maria Saibene, Carlotta Pipolo, Emanuela Fuccillo, Cecilia Rosso, Giovanni Felisati, Loredana De Pasquale
Summary: The present study reports the experience from a single center on 111 cases of advanced thyroid cancers, and evaluates factors such as radical excision rate, complications, quality of life, and survival rates. The results are critically appraised and compared to existing published evidence.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Zhi-Yong Shi, Sheng-Xiao Zhang, Di Fan, Cai-Hong Li, Zhe-Hao Cheng, Yan Xue, Li-Xiang Wu, Ke-Yi Lu, Su-Yun Yang, Yan Cheng, Zhi-Fang Wu, Chong Gao, Xiao-Feng Li, Hai-Yan Liu, Si-Jin Li
Summary: In this study, the effects of total thyroidectomy and radioactive iodine therapy on immune function in patients with differentiated thyroid carcinoma (DTC) were investigated. The results showed that both treatments caused changes in immune function, particularly in regulatory T cells and various lymphocyte subgroups. The percentage of Th17 cells before treatment may serve as a significant predictor of poor prognosis in DTC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Surgery
Takaaki Oba, Kazuma Maeno, Nami Kiyosawa, Hiroki Morikawa, Masatsugu Amitani, Tatsunori Chino, Tadafumi Shimizu, Mayu Ono, Tokiko Ito, Toshiharu Kanai, Takeshi Uehara, Ken-ichi Ito
Summary: Diagnosis of poorly differentiated thyroid cancer (PDTC) in Japan requires >= 50% of poorly differentiated components (PDC), but the optimal cutoff percentage of PDC remains controversial. This study found that PTC with >= 50% PDC is more aggressive than pure PTC or PTC with < 50% PDC, and NLR may reflect the PDC proportion.
JOURNAL OF SURGICAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Jelena Lukovic, Irina Petrovic, Zijin Liu, Susan M. Armstrong, James D. Brierley, Richard Tsang, Jesse D. Pasternak, Karen Gomez-Hernandez, Amy Liu, Sylvia L. Asa, Ozgur Mete
Summary: The study aimed to review the clinicopathologic characteristics, outcome, and RAI use in patients with oncocytic papillary thyroid carcinoma and oncocytic poorly differentiated thyroid carcinoma. Patients with oncocytic PTC showed excellent clinical outcomes and similar risk factors for recurrence as non-oncocytic counterparts, while oncocytic PDTC patients exhibited a higher frequency of DM and lower RAI uptake.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Medicine, General & Internal
Chen-Yuan Lin, Jeffrey S. Chang, Shih-Ming Huang, Chung-Jye Hung, Chien-Ling Hung, Chwen-Tzuei Chang, Horng-Ren Yang, Te-Chun Hsieh, Yu-Hui Huang, Hui-Jen Tsai
Summary: In this study, we investigated the real-world experience of sorafenib in treating advanced DTC patients in Taiwan. Most patients started with a dose of 200 mg twice daily and had a mean daily maintenance dose of 433 mg. The most common toxicity of sorafenib was hand foot skin reaction (69%), followed by diarrhea (42%), and skin rash (33%).
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Article
Oncology
Dauren Adilbay, Avery Yuan, Paul B. Romesser, Richard J. Wong, Jatin P. Shah, Ashok R. Shaha, Michael R. Tuttle, Snehal Patel, Nancy Y. Lee, Ian Ganly
Summary: This study aimed to report the experience of patients with well-differentiated thyroid cancer (WDTC) who received postoperative radiation therapy (PORT). The results showed that patients who received PORT had improved locoregional recurrence-free probability, but it did not translate into improved disease-specific survival and overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Yasuhiro Ito, Naoyoshi Onoda, Takumi Kudo, Hiroo Masuoka, Takuya Higashiyama, Minoru Kihara, Akihiro Miya, Akira Miyauchi
Summary: The study found that lenvatinib (LEN) may be more effective than sorafenib (SOR) in patients with radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC), with a higher partial response rate. After LEN treatment, the levels of serum thyroglobulin significantly decreased in patients, but the choice of first-line drug should be based on individual patient characteristics and adverse events.
Article
Biochemistry & Molecular Biology
Seok-Mo Kim, Keunwan Park, Jin Hong Lim, Hyeok Jun Yun, Sang Yong Kim, Kyung Hwa Choi, Chan Wung Kim, Jae Ha Lee, Raymond Weicker, Cheol-Ho Pan, Ki Cheong Park
Summary: In the treatment of therapy-refractory papillary thyroid carcinoma (PTC), the discovery of SERCA as an essential factor for cell survival provides a potential target for developing drugs. The novel SERCA inhibitors show promising results in reducing tumors in therapy-resistant PTC cells, providing a basis for developing a combination therapy for targeting extremely malignant cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Jonghwa Ahn, Meihua Jin, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jung Hwan Baek, Dong Eun Song, Min Ji Jeon
Summary: This study aims to evaluate the role of FNA and CNB in the preoperative diagnosis of TCV-PTC. The findings suggest that both FNA and CNB have limitations in predicting TCV-PTC.
CLINICAL ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
Summary: This study aimed to evaluate the clinical efficacy and safety of sorafenib and lenvatinib as first-line treatment for RAI-refractory DTC. The results showed that lenvatinib had a longer PFS and more common adverse events compared to sorafenib.
Article
Radiology, Nuclear Medicine & Medical Imaging
Boeun Lee, Sae Rom Chung, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee, Jung Hwan Baek
Summary: The purpose of this study was to assess the diagnostic role of fine-needle aspiration cytology (FNAC) and analyze factors associated with false-negative FNAC results in patients with parathyroid incidentaloma. The results showed that FNAC had low sensitivity for diagnosing parathyroid incidentaloma, and measuring washout parathyroid hormone (PTH) can improve diagnostic accuracy. Obtaining two or more FNA samples can reduce the false-negative rate.
Editorial Material
Oncology
Hyunju Park, Jung Heo, Chang-Seok Ki, Jung Hee Shin, Young Lyun Oh, Young Ik Son, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung, Tae Yong Kim, Tae Hyuk Kim, Jung-Han Kim
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Hyunju Park, Jung Heo, Chang-Seok Ki, Jung Hee Shin, Young Lyun Oh, Young Ik Son, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung, Tae Yong Kim, Tae Hyuk Kim, Jung-Han Kim
Summary: This study aimed to clarify the selection criteria for completion thyroidectomy using telomerase reverse transcriptase (TERT) promoter mutation. The results showed that 2 cm was a critical threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death in minimally invasive and encapsulated angioinvasive follicular thyroid carcinoma with mutant TERT. For follicular thyroid carcinoma with wild-type TERT, the critical diameter was 4 cm.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung Sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im, Hye Seong Ahn, Hyun Lim, Hyung-Don Kim, Jae-Joon Kim, Jeong Il Yu, Jeong Won Lee, Ji Yeon Park, Jwa Hoon Kim, Kyoung Doo Song, Minkyu Jung, Mi Ran Jung, Sang-Yong Son, Shin-Hoo Park, Soo Jin Kim, Sung Hak Lee, Tae-Yong Kim, Woo Kyun Bae, Woong Sub Koom, Yeseob Jee, Yoo Min Kim, Yoonjin Kwak, Young Suk Park, Hye Sook Han, Su Youn Nam, Seong-Ho Kong
Summary: This is the fourth gastric cancer guideline published in Korea, revised in 2018 based on evidence-based approach. It is a collaborative work of an interdisciplinary working group and includes 33 updated or proposed key questions, with 40 statements developed based on systematic review. The evidence level and recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. The guideline covers screening, diagnosis, staging and follow-up.
JOURNAL OF GASTRIC CANCER
(2023)
Correction
Endocrinology & Metabolism
Won Gu Kim, Won Bae Kim, Gyeongji Woo, Hyejin Kim, Yumi Cho, Tae Yong Kim, Sun Wook Kim, Myung-Hee Shin, Jin Woo Park, Hai-Lin Park, Kyungwon Oh, Jae Hoon Chung
ENDOCRINOLOGY AND METABOLISM
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
So Yeong Jeong, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Ki-Wook Chung, Tae Yong Kim, Jeong Hyun Lee
Summary: The study aimed to evaluate the technical feasibility, efficacy, and safety of anterolateral hydrodissection (ALHD) in radiofrequency ablation (RFA) for benign thyroid nodules. ALHD technique was technically feasible and effective in all patients, achieving a mean initial ablation ratio (IAR) of 90.7%. The ALHD technique also had a pain-relieving effect, resulting in only low amounts of lidocaine administration being required during the procedure.
Letter
Oncology
Hyunju Park, Tae Yong Kim, Tae Hyuk Kim, Jung-Han Kim
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Meihua Jin, Chae A. Kim, Dong Jun Bae, Sang-Yeob Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim, Min Ji Jeon
Summary: This study evaluated changes in the peripheral blood immune cell population in patients with advanced thyroid cancer receiving lenvatinib treatment to confirm the immune-modulatory effect of lenvatinib. After obtaining informed consent from patients, we prospectively collected 20 ml of whole blood at 2-3 months intervals 2-4 times from each patient; peripheral blood mononuclear cells (PBMCs) were separated, and the Maxpar Direct Immune Profiling Assay was performed. A total of 10 patients were enrolled, and 31 blood samples were obtained. The proportion of peripheral natural killer (NK) cells significantly increased during lenvatinib treatment in advanced thyroid cancer patients, confirming the immune-modulatory effect of lenvatinib.
SCIENTIFIC REPORTS
(2023)
Article
Endocrinology & Metabolism
Ahreum Jang, Meihua Jin, Chae A. Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Summary: The role of measuring serum thyroglobulin (Tg) levels in predicting the recurrence of papillary thyroid carcinoma (PTC) after lobectomy was investigated. It was found that there was no significant difference in serum Tg levels between the recurrence and non-recurrence groups, and the Tg levels did not show an increasing trend in the recurrence group. Regular monitoring of Tg levels provides little benefit in predicting recurrence for PTC patients who underwent lobectomy.
Article
Endocrinology & Metabolism
Meihua Jin, Mijin Kim, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Dong Jun Lim, Won Gu Kim
Summary: This study aimed to evaluate the predictive ability of inflammatory biomarkers for the prognosis of progressive RAI-refractory thyroid cancer patients treated with sorafenib. The results showed that low lymphocyte-to-monocyte ratio (LMR) and high neutrophil-to-lymphocyte ratio (NLR) were associated with poorer progression-free survival (PFS), while high LMR, low NLR, and low platelet-to-lymphocyte ratio (PLR) were associated with prolonged overall survival (OS).
Article
Endocrinology & Metabolism
Chae A. Kim, Jungmin Yoo, Hye-Seon Oh, Min Ji Jeon, Sae Rom Chung, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Summary: This study assessed the clinical outcomes of small, highly suspicious nodules lacking initial cytological confirmation. The study found that these nodules had a low disease progression rate without fine needle aspiration (FNA), and disease progression was associated with the growth rate of the nodules.